Company / Operating Income per Share
RAPT Therapeutics, Inc. Operating Income per Share History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$3.34
FY2024
5-year range
-$3.34 / -$2.20
FY2020-FY2024
Trend
-0.7%
vs FY2023
Sector context
#144 of 196
Health Care
What the data says
At $-3.34, RAPT Therapeutics, Inc.'s operating income per share ranks #144 of 196 in the Health Care sector. Operating Income per Share has declined for 4 consecutive years, from $-2.20 in FY2020 to $-3.34 in FY2024.
Based on SEC 10-K filings.
-3.34 in FY2024.
Declined from $-2.64 to $-3.34 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#144 of 196 in Health CareTop 73% of 196This company -$3.34 Sector average -$46.00
▼
+92.7% above sector average
Key checks
Key Insights
- RAPT Therapeutics, Inc.'s operating income per share has declined for 4 consecutive years.
- In FY2024, operating income per share decreased 0.7% year-over-year.
- Ranks #144 out of 196 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$3.34 | -0.7% |
| FY2023 | -$3.31 | -25.7% |
| FY2022 | -$2.64 | -4.3% |
| FY2021 | -$2.53 | -14.6% |
| FY2020 | -$2.20 | +78.0% |
| FY2019 | -$10.04 | +83.1% |
| FY2018 | -$59.37 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026